Document is current
Any future updates will be listed below
-
Authors
Suto, Keito https://orcid.org/0000-0001-8212-5664
Takei, Norio
Yokoyama, Keito
Chiba, Masahiro https://orcid.org/0000-0003-2731-6091
Ishio, Takashi
Maeda, Michiyuki
Goto, Hideki
Endo, Tomoyuki
Teshima, Takanori https://orcid.org/0000-0002-0941-271X
Yang, Yibin https://orcid.org/0000-0002-9948-8696
Nakagawa, Masao https://orcid.org/0000-0002-8602-6054
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP21H02775, 23K15314)
Takeda Pharmaceutical Company (NA)
Princess Takamatsu Cancer Research Fund (NA)
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA259188, R01 CA251674)
American Cancer Society (RSG-23-722314)
Leukemia and Lymphoma Society (NA)
- License Information
-
More Information
Article History
Received: 19 March 2024
Revised: 9 October 2024
Accepted: 11 October 2024
First Online: 21 October 2024
Competing interests
: MN received research funding from Takeda Pharmaceutical Company Limited. The other authors declare no competing financial interests related to this work.
